APA (7th ed.) Citation

Wu, Y., Lee, N., Liu, Y. C., Kim, M. S., Hwang, S., Kim, B., . . . Kim, S. M. (2026). Recombinant bone morphogenetic protein-2 attenuates colorectal cancer progression by orchestrating Hippo pathway activation, Yes-associated protein inhibition, and epithelial--mesenchymal transition suppression. Korean Journal of Physiology & Pharmacology, 30(4), 361. https://doi.org/10.4196/kjpp.25.369

Chicago Style (17th ed.) Citation

Wu, Yanling, Na-Ri Lee, Yu Chuan Liu, Min Sun Kim, Seongwon Hwang, Bumseok Kim, Kwang-Bok Lee, and Soo Mi Kim. "Recombinant Bone Morphogenetic Protein-2 Attenuates Colorectal Cancer Progression by Orchestrating Hippo Pathway Activation, Yes-associated Protein Inhibition, and Epithelial--mesenchymal Transition Suppression." Korean Journal of Physiology & Pharmacology 30, no. 4 (2026): 361. https://doi.org/10.4196/kjpp.25.369.

MLA (9th ed.) Citation

Wu, Yanling, et al. "Recombinant Bone Morphogenetic Protein-2 Attenuates Colorectal Cancer Progression by Orchestrating Hippo Pathway Activation, Yes-associated Protein Inhibition, and Epithelial--mesenchymal Transition Suppression." Korean Journal of Physiology & Pharmacology, vol. 30, no. 4, 2026, p. 361, https://doi.org/10.4196/kjpp.25.369.